Metastatic Cancer Clinical Trial
Official title:
Early Assessment of Anti-Angiogenic Treatment Efficacy in Advanced Renal Cancer by Using Contrast-Enhanced Sonography
RATIONALE: Diagnostic procedures, such as contrast-enhanced ultrasound, may help measure a
patient's response to treatment with drugs such as sunitinib malate, sorafenib tosylate, or
bevacizumab, and allow doctors to plan better treatment.
PURPOSE: This clinical trial is studying ultrasonography in assessing antiangiogenic
treatment in patients with advanced kidney cancer.
OBJECTIVES:
Primary
- To determine if contrast-enhanced ultrasonography (CEUS) study of target metastasis
from renal cancer leads to early assessment of pharmacodynamic effects of
antiangiogenic treatment in patients with advanced renal cancer.
Secondary
- To determine the association between functional changes of microvascularization and the
target lesion by CEUS and the early objective response for this lesion indicated by the
time to progression.
- To determine the association between functional changes of microvascularization and the
target lesion by CEUS and the early objective response for this lesion indicated by the
global survey.
- To determine the tolerance to antiangiogenic treatments in these patients.
- To determine the relationship between functional changes of microvascularization and
the target lesion and the objective response for the other lesions (RECIST criteria) in
cases of other metastasis other than the target lesion.
OUTLINE: Patients undergo contrast-enhanced ultrasonography (CEUS) before and after
stabilized sulphur hexafluoride microbubble-based contrast agent injection. CEUS is done
within 8 days prior to, 30 days after the first administration, and after 3 months of
receiving antiangiogenesis treatment (e.g., sunitinib malate, sorafenib tosylate, or
bevacizumab). Patients also undergo computed tomography and magnetic resonance imaging to
evaluate tumoral targets.
After completion of study treatment, patients are followed up for 2 years.
;
Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Recruiting |
NCT05798611 -
Study of ART0380 in Patients With Biologically Selected Solid Tumors
|
Phase 2 | |
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05036681 -
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
|
Phase 2 | |
| Withdrawn |
NCT00005030 -
SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
|
Phase 1 | |
| Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
| Recruiting |
NCT04085029 -
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
|
||
| Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05981170 -
Rurality Adapted Physical Activity Sport Health
|
||
| Not yet recruiting |
NCT03058809 -
Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood
|
Phase 1/Phase 2 | |
| Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
| Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
| Terminated |
NCT00918645 -
Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis
|
N/A | |
| Completed |
NCT01302808 -
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
|
Phase 1 | |
| Withdrawn |
NCT00769990 -
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
|
Phase 1/Phase 2 | |
| Completed |
NCT00795678 -
Chemotherapeutic Agents in Brain/Breast
|
N/A | |
| Completed |
NCT00557102 -
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
|
Phase 2 | |
| Recruiting |
NCT00398437 -
Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer
|
N/A |